Several lines of evidence suggest that CML is sensitive to immunotherapy [19], and that responses to TKI therapy can be determined not only by direct binding capacity for BCR::ABL but also by anti-tumor immune responses [20, 21]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.